- My Forums
- Tiger Rant
- LSU Recruiting
- SEC Rant
- Saints Talk
- Pelicans Talk
- More Sports Board
- Fantasy Sports
- Golf Board
- Soccer Board
- O-T Lounge
- Tech Board
- Home/Garden Board
- Outdoor Board
- Health/Fitness Board
- Movie/TV Board
- Book Board
- Music Board
- Political Talk
- Money Talk
- Fark Board
- Gaming Board
- Travel Board
- Food/Drink Board
- Ticket Exchange
- TD Help Board
Customize My Forums- View All Forums
- Show Left Links
- Topic Sort Options
- Trending Topics
- Recent Topics
- Active Topics
Started By
Message
0
Posted on 1/23/21 at 10:15 am to LChama
quote:
Does this drug have crossover potential into the realm of heart transplant patients as an alternative to cyclosporin?
Maybe
If that were demonstrated in clinical trials.
Posted on 1/23/21 at 10:20 am to Rendevoustavern
quote:
That adds up fast and is 7-8 billing items as compared to a dr visit and a script
That is the biggest thing. Which feeds into where it is on formulary. If there is any kind of step therapy, being ahead of Benlysta would make a huge difference.
Posted on 1/23/21 at 10:20 am to bayoubengals88
quote:
Define blockbuster if you would.
Billion dollar a year
Posted on 1/23/21 at 10:20 am to HangingWithMrCooper
quote:That's harsh. He's been fairly reasonable for the most part.
There are just some miserable people in this world, this thread has been nothing but positive and someone new comes in and starts farting and stinking the place up.
Posted on 1/23/21 at 10:23 am to Rendevoustavern
quote:
Rendevoustavern
Baw, chill
quote:
The frick do you know about pharmaceuticals?
I've worked in the industry for 20 years.
I think the approval is amazing. My buddies wife actually has lupus. I'm just asking some questions and taking an objective view. Sorry for rustling your jimmies.
I'm not even sure what i said that is so offensive.
This post was edited on 1/23/21 at 11:05 am
Posted on 1/23/21 at 10:50 am to Chucktown_Badger
so is it a consensus that they are working on a buyout or is that still up in the air?
Posted on 1/23/21 at 11:09 am to rocket31
I'm seeing peak sales estimates that are all over the place. One was $2B, which is certainly blockbuster.
Posted on 1/23/21 at 12:18 pm to Chucktown_Badger
quote:Many reports have called Voc a potential blockbuster drug, and I’ve seen plenty call 1B a conservative estimate over the years.
I'm seeing peak sales estimates that are all over the place. One was $2B, which is certainly blockbuster.
They are set up for royalties in Asia, and have done ALL the leg work to get started. I’ve been extremely impressed by Glickman and Greenleaf over the years. When you get a chance, check out who’s on their team. Everyone in management has experience in big pharma...some for decades.
I don’t think 6B is absurd. They will issue extremely conservative guidance soon. Time will tell.
Posted on 1/23/21 at 12:19 pm to rocket31
quote:100% set up to go it alone, but open to buyout. They’ve played their cards as well as can be expected.
so is it a consensus that they are working on a buyout or is that still up in the air?
Posted on 1/23/21 at 12:29 pm to bayoubengals88
I think th current us market for former treatments was like 3b i feel like I read somewhere. This is of course a better treatment option.
Posted on 1/23/21 at 12:36 pm to bayoubengals88
quote:
00% set up to go it alone, but open to buyout.
You know if they have their own sales force, or are they using a contract sales force?
Posted on 1/23/21 at 1:06 pm to Chucktown_Badger
quote:
You know if they have their own sales force, or are they using a contract sales force?
Is this the same thing?
March 2020:
quote:
We are thrilled to announce the opening of our U.S. commercial offices in Montgomery County, Maryland, as we continue to advance the development of voclosporin, which has the potential to become the first-ever approved treatment for patients suffering from lupus nephritis. This important milestone follows the recent build-out of our commercial leadership team, as we move swiftly, yet responsibly, toward commercial readiness,” said Peter Greenleaf, President and Chief Executive Officer of Aurinia.
quote:
Aurinia also announced on February 25, 2020, the appointment of Max Colao, to the newly created role of Chief Commercial Officer, along with the addition of a team of experts across key commercial functions in preparation for the potential commercial launch of voclosporin in early 2021.
quote:
Aurinia... today announced the appointment of Max Colao to the newly created position of Chief Commercial Officer. In addition, Aurinia has recruited an experienced team of leaders across key commercial functions including sales, marketing, market access, and commercial operations.
quote:
Joining the commercial organization along with Mr. Colao are:
Chris Hays, Vice President, Marketing;
Fran Lynch, Vice President, Sales;
Cara Felish, Vice President, Commercial Operations; and
Tim Hermes, Vice President, Market Access.
These hires follow the recently reported positive efficacy and safety results from the Company’s AURORA Phase 3 trial in the treatment of LN. Voclosporin was granted Fast Track designation by the FDA in 2016.
This post was edited on 1/23/21 at 1:12 pm
Posted on 1/23/21 at 1:12 pm to bayoubengals88
quote:
Max Colao brings nearly 30 years of world-class commercial operations experience to his role at Aurinia. Prior to leading U.S. commercial operations at Alexion and launching multiple rare disease therapies, Mr. Colao spent nearly 20 years at Amgen, holding roles of increasing responsibility on various marketing and sales teams, most notably leading U.S. launches, commercialization, and pricing strategy in the areas of rheumatology, dermatology, and autoimmune disorders for Enbrel®, Prolia®, and Nplate®.
quote:Damn
Fran Lynch brings a wide range of sales experience across multiple areas of business to his role at Aurinia. Most recently, Mr. Lynch was responsible for expanding the sales force at UCB to prepare for the launch of bimekizumab. Prior to UCB, he was responsible for building out commercial teams at Sun Pharmaceuticals, Takeda Pharmaceuticals, and Human Genome Sciences (HGS). At HGS, he was responsible for the build out of sales and leadership for the launch of BENLYSTA (belimumab), for systemic lupus erythematosus (SLE).
This post was edited on 1/23/21 at 1:13 pm
Posted on 1/23/21 at 3:26 pm to bayoubengals88
quote:
Prior to UCB, he was responsible for building out commercial teams at Sun Pharmaceuticals, Takeda Pharmaceuticals, and Human Genome Sciences (HGS). At HGS, he was responsible for the build out of sales and leadership for the launch of BENLYSTA (belimumab), for systemic lupus erythematosus (SLE).
So the whole reason thst I was sold on this thing back in the day was the team they had together. They seem to have continued to hire well.
Posted on 1/23/21 at 4:16 pm to oklahogjr
Doesn’t look like they are setting up for a buyout
Posted on 1/23/21 at 4:27 pm to bayoubengals88
quote:
Is this the same thing?
He would be the one overseeing the sales force, so maybe they have salaried reps.
This post was edited on 1/23/21 at 4:29 pm
Posted on 1/23/21 at 7:02 pm to jimjackandjose
quote:
Doesn’t look like they are setting up for a buyout
Why so?
Companies that NEED a buyout get bought cheap. Since when is negotiating from a position of strength a bad thing?
For example, this November Motley Fool article assumed a weaker, somewhat needy AUPH. The result? A 3.5 to 4 billion dollar price tag.
But now that we know that AUPH is commercially derisked, due to being set up for immediate sales....well, the price just went up!
The article excerpt listing AUPH as the #1 Biogen takeover candidate:
quote:
1. Aurinia Pharmaceuticals (NASDAQ:AUPH) is marching toward a January decision date with the FDA for its lupus nephritis drug candidate voclosporin. If approved, voclosporin is expected to generate between $770 million and $1 billion as a treatment for lupus nephritis. Even so, Aurinia's market cap is only $1.7 billion at present. The market seems to be betting against a fast launch for voclosporin, presumably as a result of Aurinia's limited commercial infrastructure.
What's key to understand is that Biogen has a deep interest in lupus medications, and Aurinia might be able to be had for as little as $3.5 billion to $4 billion. A buyout would also take the risk of a commercial launch off the table for Aurinia shareholders. A merger would thus be a win-win for the stakeholders of both Aurinia and Biogen.
Posted on 1/24/21 at 1:30 pm to Chucktown_Badger
quote:“We’re in the starter’s blocks, ready for the gun to go off. We’ve had a fully deployed salesforce since early December, ready to ship the drug and launch,” Aurinia CEO Peter Greenleaf said in an interview with STAT conducted before the Lupkynis approval.
You know if they have their own sales force, or are they using a contract sales force?
Posted on 1/24/21 at 1:32 pm to Chucktown_Badger
quote:
Define blockbuster if you would.
quote:
Billion dollar a year
STAT article from yesterday:
quote:
Aurinia estimates that approximately 80,000 patients in the U.S. would be eligible for treatment with voclosporin — a revenue opportunity that tops $1 billion annually even if just one-quarter of eligible lupus nephritis patients end up on the drug.
Page 59 of 164
Popular
Back to top
Follow TigerDroppings for LSU Football News